FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/08/071856 [Registered on: 02/08/2024] Trial Registered Prospectively
Last Modified On: 31/07/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Cosmeceuitcal ]  
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Effect of products on pimples  
Scientific Title of Study   To evaluate and compare the in-vivo safety and efficacy of the skin care formulations in terms of reduction in Acne (live/occurring) on healthy female subjects 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
XXX-ZF01-CJ-MY24; Version: Final 01; 09/07/2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Pooja Yadav 
Designation  Principal Investigator 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, Appasaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai, Maharashtra

Mumbai
MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  poojayadav@mascotspincontrol.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Pooja Yadav 
Designation  Principal Investigator 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, Appasaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai, Maharashtra


MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  poojayadav@mascotspincontrol.in  
 
Details of Contact Person
Public Query
 
Name  Dr Mohit Lalvani 
Designation  Study Director 
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd. 
Address  Sea Breeze Building, 9th Floor, Appasaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai, Maharashtra

Mumbai
MAHARASHTRA
400025
India 
Phone  02243349191  
Fax    
Email  mohit.CTRI@gmail.com  
 
Source of Monetary or Material Support  
Cureskin Ground Floor, 171, HSIDC, Sector 2, Saha, Amabala. Haryana – 133104 
 
Primary Sponsor  
Name  Cureskin 
Address  Ground Floor, 171, HSIDC, Sector 2, Saha, Amabala. Haryana – 133104 
Type of Sponsor  Other [FMCG] 
 
Details of Secondary Sponsor  
Name  Address 
NIL   NA 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Pooja Yadav  Mascot Spincontrol India Pvt. Ltd.   Sea Breeze Building, 9th Floor, Appasaheb Marathe Marg, Century Bazaar, Prabhadevi, Mumbai, Maharashtra
Mumbai
MAHARASHTRA 
02243349191

poojayadav@mascotspincontrol.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Ethos- An Institutional Ethics committee (Mumbai)   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  having mild to moderate acne and oily to mixed oily skin type 
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Nil  NA 
Intervention  Regime 1  Regime consisted of 4 products, all the products will be applied on whole face for the period of 28days. 
Intervention  Regime 2  Regime consisted of 4 products, all the products will be applied on whole face for the period of 28days. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  30.00 Year(s)
Gender  Female 
Details  1. Indian female subjects
2. Healthy subjects
3. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
4 Having mild to moderate acne and oily to mixed oily skin type 
 
ExclusionCriteria 
Details  1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
2. Having refused to give her/his assent by not signing the consent form
3. Taking part in another study liable to interfere with this study
4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
5. Having a progressive asthma (either under treatment or last fit in the last 2 years)
6. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
7. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
8. Being epileptic.
9. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
10. Having cutaneous hypersensitivity.
11. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
12. Having undergone a surgery requiring a general anesthetic of more than one hour in the past 6
months. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
Reduction in Acne  Baseline, Day 14, Day 28 
 
Secondary Outcome  
Outcome  TimePoints 
Nil  NA 
 
Target Sample Size   Total Sample Size="72"
Sample Size from India="72" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1/ Phase 2 
Date of First Enrollment (India)   11/08/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

The objective of this study will be to evaluate and compare the in-vivo safety and efficacy of the skin care formulations in terms of reduction in Acne (live/occurring) on healthy female subjects.

 

Products: Regime1 and Regime 2

 

The evaluation is performed using: Subject Self Evaluation (SSE),  Dermatological : Cosmetic Acceptability, Dermatological Evaluation: Efficacy

 

The study lasts 28 days following the first application of the regime on whole face.

 

POPULATION - 72 Females subjects will be selected for the study.

The subjects selected for this study are healthy females, aged between 18 and 30 years, having mild to moderate acne and oily to mixed oily skin type.

The study will be conducted in 2 groups.

I. Group A: This group will include 36 female subjects using Regime 1.

II. Group B: This group will include 36 female subjects using Regime 2.

 
Close